Three Hundred Missing Hydrocodone Tablets and a Bag of Patient Returns
At a three-pharmacist independent pharmacy in Duluth, the quarterly controlled substance reconciliation is completed. Hydrocodone/acetaminophen 5/325: the April 1 inventory showed 1,200 tablets; purchases since then total 900; the dispensing records show 1,750; today's count is 50. Expected on hand is 350, so 300 tablets are unaccounted for. The PMP reports match the dispensing records. The safe has a mechanical lock with a code shared by six employees, last changed when an employee left in February. An evening technician has recently had "family problems" and has been seen leaving with a backpack. Separately, a long-term patient brings in 120 tablets of oxycodone 10 mg left over from her late husband, still in pharmacy-labeled vials, and asks that they be "put back or at least destroyed." Two weeks ago the pharmacy also received a shipment with four broken bottles of lorazepam 1 mg, a Schedule IV drug.
1. Is the 300-tablet shortage a reportable loss? Set out what must be filed, with whom, and on what timeline, and what should happen before any report is filed.
Read the worked answer
Characterize it first. Three hundred Schedule II tablets is significant on its face; the analysis considers the quantity, the schedule, the pattern over time, and whether the drug could have been diverted. A shortage this size is not a rounding error, and the fact that dispensing records and PMP reports reconcile means the loss occurred on the inventory side - receiving, storage, or removal - not at the dispensing counter.
Reports: (1) DEA Form 106, filed in writing as soon as discovery is made - in practice within one business day - describing the drug, quantity, and circumstances, with a copy retained. (2) The Minnesota Board of Pharmacy, in writing, in the form and timeframe its rules require for theft or significant loss, with an honest account and a remediation plan. (3) Local police. Investigators from both agencies will ask whether a police report exists, and a police report also protects the pharmacy against later allegations of concealment.
Before filing: secure the remaining stock - change the safe code now and restrict it to the pharmacist-in-charge and one designee; preserve camera footage, access logs, purchase invoices, and the reconciliation worksheet; and expand the audit to every controlled substance, because a 300-tablet gap is rarely isolated. Do not wait to "finish the investigation," and do not confront the suspected technician alone. Reporters should stick to what is known and update as facts develop.
2. How should the 120 returned oxycodone tablets and the four broken lorazepam bottles be handled, and what documentation is required?
Read the worked answer
The returned oxycodone is never going back into stock. Once a controlled substance has been dispensed to a patient it cannot be redispensed, regardless of whether the vial is sealed. Accepting it is a handling event, not a dispensing event, and the pharmacy must choose a lawful destruction channel: transfer to a DEA-registered reverse distributor with a record of drug, strength, quantity, date, patient or "patient return," recipient, and both signatures; destruction on site by the registrant with at least two employees witnessing and a written destruction record including date, drug, quantity, method, and signatures (the registrant reports its own destruction on DEA Form 41); or, if the pharmacy is a registered collector, a compliant collection receptacle or mail-back envelope. Patient-return policies should be written, and staff should never tell a patient to flush or trash a controlled substance when a take-back option exists.
The broken lorazepam is a different transaction: it is a receipt loss, not a patient return. Note the damage on the receiving record, obtain the wholesaler's breakage credit documentation, quarantine the bottles so no one dispenses from them, and route them through the same reverse distributor or witnessed-destruction process. Schedule IV drugs are still controlled substances; putting them in the dumpster is a violation. Keep all destruction and transfer records with the controlled substance records for the required retention period and make them available on inspection.
3. What inventory and record-retention requirements should this pharmacy have been meeting, and where did it likely fall short?
Read the worked answer
Federal requirements: an initial inventory, then a biennial inventory of all controlled substances on any date chosen by the registrant within two years of the prior one, taken at opening or close of business, with the date and time recorded and signed by the person(s) taking it. Schedule II counts are exact; Schedule III through V may be estimated unless the container holds more than 1,000 units, in which case an exact count is required. Newly scheduled substances must be inventoried on their effective date. Records - invoices, dispensing records, inventories, Forms 106 and 41, and destruction records - are kept at the registered location for at least two years and must be readily retrievable.
Minnesota adds that a new inventory is required when the pharmacist-in-charge changes, and its records rules require prescription and controlled substance records to be maintained and available for Board inspection.
Where this pharmacy fell short: a code shared by six employees is not effective access control; a departure in February without a code change or an exit inventory is a gap; and a quarterly spreadsheet reconciliation without a perpetual inventory for Schedule II cannot detect diversion quickly. The fix is structural - unique access credentials or a key log, a perpetual Schedule II log with a second-person count at each shift change, monthly rather than quarterly reconciliation, and a written policy on reporting losses that names who decides and who files. The personnel suspicion should be handled through the investigation and human resources, not by accusation.